Immune Cell Engager Therapy for Brain Cancer
Cet article passe en revue les avancées récentes concernant le traitement des tumeurs cérébrales par anticorps multispécifiques engageant les cellules immunitaires puis identifie les facteurs entravant leur généralisation
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.Brain tumors are among the most difficult cancers to treat. Standard treatments, including surgery, radiation therapy, and chemotherapy, can help some patients but often do not cure the disease. They may also cause side effects that affect brain function, and they are often less effective when the cancer grows or spreads. Because of these limitations, new treatment approaches are urgently needed. One promising strategy is immunotherapy, which helps the body's immune system recognize and attack cancer cells. Scientists have recently developed new antibody-based therapies that are designed to target proteins found on brain tumor cells while also activating immune cells to destroy them. In this review, we summarize recent progress in these multi-specific immune cell engager therapies for brain tumors and discuss the challenges that remain before they can become widely available treatments.
Neuro-Oncology , article en libre accès, 2026